Free Trial

iHuman Inc. Sponsored ADR (NYSE:IH) Short Interest Up 280.0% in September

iHuman logo with Consumer Discretionary background

Key Points

  • iHuman Inc. saw a significant increase in short interest in September, rising by 280.0% to a total of 1,900 shares as of September 30th from 500 shares on September 15th.
  • The company reported earnings of $0.08 per share and revenue of $27.94 million for the recent quarter, with a net margin of 12.46%.
  • Virtu Financial LLC has acquired a new stake in iHuman, purchasing 12,150 shares valued at approximately $26,000, making institutional ownership about 4.92% of the stock.
  • MarketBeat previews the top five stocks to own by November 1st.

iHuman Inc. Sponsored ADR (NYSE:IH - Get Free Report) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 1,900 shares, an increase of 280.0% from the September 15th total of 500 shares. Based on an average daily volume of 33,100 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 33,100 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of iHuman

A hedge fund recently bought a new stake in iHuman stock. Virtu Financial LLC acquired a new position in shares of iHuman Inc. Sponsored ADR (NYSE:IH - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,150 shares of the company's stock, valued at approximately $26,000. 4.92% of the stock is owned by institutional investors and hedge funds.

iHuman Price Performance

NYSE:IH traded down $0.17 during midday trading on Friday, reaching $2.70. The stock had a trading volume of 26,479 shares, compared to its average volume of 16,887. The stock has a market capitalization of $138.65 million, a P/E ratio of 9.31 and a beta of 0.40. iHuman has a 1-year low of $1.47 and a 1-year high of $3.60. The firm's fifty day simple moving average is $2.83 and its 200-day simple moving average is $2.52.

iHuman (NYSE:IH - Get Free Report) last released its earnings results on Thursday, September 18th. The company reported $0.08 earnings per share for the quarter. The firm had revenue of $27.94 million during the quarter. iHuman had a net margin of 12.46% and a return on equity of 11.59%.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a "hold (c+)" rating on shares of iHuman in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, iHuman has a consensus rating of "Hold".

Get Our Latest Research Report on iHuman

iHuman Company Profile

(Get Free Report)

iHuman Inc provides intellectual development products to individual users, kindergartens, and distributors in the People's Republic of China. The company offers interactive and self-directed learning apps, including iHuman Chinese, iHuman ABC, iHuman Pinyin, iHuman Magic Thinking, iHuman Books, iHuman Stories, iHuman Reading, iHumanpedia, iHuman Kids Workout, iHuman Coding, iHuman Fun Idioms, iHuman Little Artists, iHuman Writing, iHuman Fantastic Friends, and iHuman Readers; bekids Coding, bekids Coloring, bekids Reading, bekids Puzzle, bekids Academy, and Gogo Town; and Aha World, an open-ended interactive app that nurtures a desire for discovery.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in iHuman Right Now?

Before you consider iHuman, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iHuman wasn't on the list.

While iHuman currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.